STOCK TITAN

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Omeros (OMER) announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria has been selected for podium presentation at the 2024 European Hematology Association (EHA) Hybrid Congress. OMS906 is an investigational inhibitor of MASP-3 targeting the alternative pathway of complement. The EHA Congress will take place in Madrid, Spain from June 13-16, 2024, where two additional poster presentations related to OMS906 will also be featured.

Positive
  • Selection for podium presentation at the prestigious 2024 EHA Hybrid Congress indicates recognition of Omeros 's ongoing Phase 2 study of OMS906.

  • OMS906, an investigational inhibitor of MASP-3, shows promise in improving hematologic parameters in PNH patients with suboptimal response to Ravulizumab treatment.

  • The exposure-response modeling using population PK/PD methods for OMS906 demonstrates reliable predictions of complement mature factor D, hemoglobin, and LDH responses in PNH patients.

Negative
  • The outcomes of the ongoing Phase 2 study of OMS906 in paroxysmal nocturnal hemoglobinuria have not been fully disclosed, potentially leaving investors uncertain about the future prospects of the drug.

  • While the selection for podium presentation is positive, there is always a risk of unfavorable results or challenges being presented during the congress that could impact the perception of Omeros and OMS906.

-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros’ investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional poster presentations directed to OMS906 will also be featured at the congress.

The abstracts for all three presentations are scheduled to be published on May 14, 2024 and will be available on the EHA website at ehaweb.org. Details of the congress presentations are found below.

OMS906, A Novel Alternative Pathway MASP-3 Inhibitor, Improved Hematologic Parameters in PNH Patients with Suboptimal Response to Ravulizumab Treatment: Phase 2 Dose-Finding Study Interim Results (Abstract #S189)
Session Name: s454 Clinical and translational in bone marrow failure syndromes and PNH
Date: Saturday, June 15, 2024
Podium Presentation Session Time: 4:30 p.m. CEST
Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall N102
Presenting Author: Morag Griffin MBChB, FRCPath

Clinical Pharmacology of OMS906, a Potent Inhibitor of MASP-3 and the Alternative Pathway of Complement Activation (Abstract #P834)
Date: Friday, June 14, 2024
Presentation Time: 6:00 p.m. - 7:00 p.m. CEST
Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7
Presenting Author: William Pullman MB BS, PhD, FRACP

Exposure-Response Modeling Using Population PK/PD Methods Reliably Predict Population and Individual Responses of Complement Mature Factor D, Hemoglobin and LDH in PNH Patients Exposed to OMS906 (Abstract #P1920)
Date: Friday, June 14, 2024
Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7
Presenting Author: William Pullman MB BS, PhD, FRACP

The presentation materials associated with each abstract will be made available on Omeros’ website at www.omeros.com following the congress presentations.

About OMS906

OMS906 is an investigational humanized monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The complement system plays a central role in inflammation and becomes activated as a result of tissue damage or microbial infection. Responsible for the conversion of pro-complement factor D to complement factor D, MASP-3 is believed to be the premier target in the alternative pathway – it has the lowest native circulating level and low relative clearance compared to the other alternative pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition leaves intact the lytic arm of the classical pathway, important for fighting infection. Also, unlike other components of the alternative pathway, MASP-3 is believed not to be an acute phase reactant, which could provide a significant advantage to MASP-3 inhibitors, like OMS906, over other alternative pathway inhibitors. MASP-3 inhibitors are thought to have preventive and/or therapeutic effects across a broad range of diseases including paroxysmal nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (HUS), atypical HUS, traumatic brain injury, arthritis, wet age-related macular degeneration, ischemia-reperfusion injury, transplant-related complications and other immune-related disorders.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 multi-ascending-dose clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros’ lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder and, in addition, is being developed as a therapeutic for other addictions as well as for a major complication of treatment for movement disorders. Omeros also is advancing a broad portfolio of novel immuno-oncology programs comprised of two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com.

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

IR@omeros.com

Source: Omeros Corporation

FAQ

What is the Phase 2 study of OMS906 in paroxysmal nocturnal hemoglobinuria?

The Phase 2 study of OMS906 in paroxysmal nocturnal hemoglobinuria is an ongoing clinical trial focusing on the investigational inhibitor of MASP-3 targeting the alternative pathway of complement.

When will the 2024 EHA Congress take place?

The 2024 European Hematology Association (EHA) Hybrid Congress will be held from June 13-16, 2024, in Madrid, Spain.

What is the significance of OMS906 in improving hematologic parameters in PNH patients?

OMS906 shows promise in improving hematologic parameters in paroxysmal nocturnal hemoglobinuria patients with suboptimal response to Ravulizumab treatment.

Where can I find the abstracts for the upcoming presentations at the EHA Congress?

The abstracts for the upcoming presentations at the EHA Congress will be published on May 14, 2024, and will be available on the EHA website at ehaweb.org.

Omeros Corporation

NASDAQ:OMER

OMER Rankings

OMER Latest News

OMER Stock Data

301.31M
57.94M
4.39%
44.15%
22.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SEATTLE